INDV

Company Overview — What Does INDIVIOR PLC Do?

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. INDIVIOR PLC (INDV) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Mark Crossley. With a market capitalization of $3.7B, INDV is one of the notable companies in the Healthcare sector.

INDIVIOR PLC (INDV) Stock Rating — Reduce (April 2026)

As of April 2026, INDIVIOR PLC receives a Reduce rating with a composite score of 39.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.INDV ranks #2,447 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, INDIVIOR PLC ranks #304 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

INDV Stock Price and 52-Week Range

INDIVIOR PLC (INDV) currently trades at $30.63. The stock lost $1.68 (5.2%) in the most recent trading session. The 52-week high for INDV is $38.00, which means the stock is currently trading -19.4% from its annual peak. The 52-week low is $8.64, putting the stock 254.5% above its annual trough. Recent trading volume was 2.3M shares, reflecting moderate market activity.

Is INDV Overvalued or Undervalued? — Valuation Analysis

INDIVIOR PLC (INDV) carries a value factor score of 65/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 19.23x, compared to the Healthcare sector average of 23.63x — a discount of 19%. The price-to-sales ratio is 0.75x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, INDV trades at 3.54x EV/EBITDA, versus 6.34x for the sector.

Overall, INDV's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

INDIVIOR PLC Profitability — ROE, Margins, and Quality Score

INDIVIOR PLC (INDV) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -59.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 69.9% versus the sector average of -33.1%.

On a margin basis, INDIVIOR PLC reports gross margins of 80.2%, compared to 71.5% for the sector. The operating margin is 21.1% (sector: -66.1%). Net profit margin stands at 17.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 2.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

INDV Debt, Balance Sheet, and Financial Health

INDIVIOR PLC has a debt-to-equity ratio of -156.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.71x, which may signal near-term liquidity tightness. Cash and equivalents stand at $445M.

INDV has a beta of 0.62, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for INDIVIOR PLC is 64/100, reflecting average volatility within the normal range for its sector.

INDIVIOR PLC Revenue and Earnings History — Quarterly Trend

In TTM 2026, INDIVIOR PLC reported revenue of $1.24B and earnings per share (EPS) of $1.68. Net income for the quarter was $210M. Gross margin was 80.2%. Operating income came in at $262M.

In FY 2025, INDIVIOR PLC reported revenue of $1.24B and earnings per share (EPS) of $1.68. Net income for the quarter was $210M. Gross margin was 80.2%. Revenue grew 4.3% year-over-year compared to FY 2024. Operating income came in at $262M.

In Q3 2025, INDIVIOR PLC reported revenue of $314M and earnings per share (EPS) of $0.34. Net income for the quarter was $42M. Gross margin was 73.3%. Operating income came in at $43M.

In Q2 2025, INDIVIOR PLC reported revenue of $302M and earnings per share (EPS) of $0.15. Net income for the quarter was $18M. Gross margin was 82.8%. Operating income came in at $72M.

Over the past 8 quarters, INDIVIOR PLC has demonstrated a growth trajectory, with revenue expanding from $901M to $1.24B. Investors analyzing INDV stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

INDV Dividend Yield and Income Analysis

INDIVIOR PLC (INDV) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

INDV Momentum and Technical Analysis Profile

INDIVIOR PLC (INDV) has a momentum factor score of 65/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 13/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

INDV vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, INDIVIOR PLC (INDV) ranks #304 out of 838 stocks based on the Blank Capital composite score. This places INDV in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing INDV against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INDV vs S&P 500 (SPY) comparison to assess how INDIVIOR PLC stacks up against the broader market across all factor dimensions.

INDV Next Earnings Date

No upcoming earnings date has been announced for INDIVIOR PLC (INDV) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy INDV? — Investment Thesis Summary

The quantitative profile for INDIVIOR PLC suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 65/100 suggests attractive pricing relative to fundamentals. Price momentum is positive at 65/100, suggesting the trend favors buyers. Low volatility (stability score 64/100) reduces downside risk.

In summary, INDIVIOR PLC (INDV) earns a Reduce rating with a composite score of 39.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INDV stock.

Related Resources for INDV Investors

Explore more research and tools: INDV vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare INDV head-to-head with peers: INDV vs AZN, INDV vs SLGL, INDV vs VMD.